靶向放射性核素治疗：向精准癌症治疗的演进
Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.
作者信息
Jadvar Hossein
机构信息
1 Department of Radiology, Division of Nuclear Medicine, Keck School of Medicine, University of Southern California, 2250 Alcazar St, CSC Ste 102, Los Angeles, CA 90033.
出版信息
AJR Am J Roentgenol. 2017 Aug;209(2):277-288. doi: 10.2214/AJR.17.18264. Epub 2017 May 2.
Abstract
OBJECTIVE
This article reviews recent developments in targeted radionuclide therapy (TRT) approaches directed to malignant liver lesions, bone metastases, neuroendocrine tumors, and castrate-resistant metastatic prostate cancer and discusses challenges and opportunities in this field.
CONCLUSION
TRT has been employed since the first radioiodine thyroid treatment almost 75 years ago. Progress in the understanding of the complex underlying biology of cancer and advances in radiochemistry science, multimodal imaging techniques including the concept of "see and treat" within the framework of theranostics, and universal traction with the notion of precision medicine have all contributed to a resurgence of TRT.
摘要
目的
本文综述了针对恶性肝病变、骨转移、神经内分泌肿瘤和去势抵抗性转移性前列腺癌的靶向放射性核素治疗（TRT）方法的最新进展，并讨论了该领域的挑战与机遇。
结论
自近75年前首次进行放射性碘甲状腺治疗以来，TRT就已被应用。对癌症复杂基础生物学的理解取得进展、放射化学科学的进步、包括治疗诊断学框架内“可视即治疗”概念在内的多模态成像技术，以及精准医学理念的广泛接受，都促使TRT再度兴起。
相似文献
1
Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.靶向放射性核素治疗：向精准癌症治疗的演进
AJR Am J Roentgenol. 2017 Aug;209(2):277-288. doi: 10.2214/AJR.17.18264. Epub 2017 May 2.
2
[Radionuclide therapy for cancer--what's new?].[癌症的放射性核素治疗——有哪些新进展？]
Duodecim. 2012;128(21):2209-16.
3
Radionuclide therapy beyond radioiodine.除放射性碘之外的放射性核素治疗
Wien Med Wochenschr. 2012 Oct;162(19-20):430-9. doi: 10.1007/s10354-012-0128-6. Epub 2012 Jul 20.
4
[Nuclear medicine in oncotherapy].[肿瘤治疗中的核医学]
Magy Onkol. 2015 Sep;59(3):193-7. Epub 2015 Apr 11.
5
Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.放射性药物治疗学——核医学与分子影像中的精准医学。
Nanotheranostics. 2022 Jan 1;6(1):103-117. doi: 10.7150/ntno.64141. eCollection 2022.
6
Whole-body iodine-131 metaiodobenzylguanidine imaging for detection of bone metastases in patients with paraganglioma: comparison with bone scintigraphy.用于检测副神经节瘤患者骨转移的全身碘-131间碘苄胍显像：与骨闪烁显像的比较
Ann Nucl Med. 2007 Jul;21(5):307-10. doi: 10.1007/s12149-007-0020-4. Epub 2007 Jul 25.
7
Radionuclide Therapies: An Overview of Applications.放射性核素治疗：应用概述。
Radiol Technol. 2021 Jul;92(6):595-614.
8
Radionuclide Therapies in Molecular Imaging and Precision Medicine.分子成像与精准医学中的放射性核素疗法
PET Clin. 2017 Jan;12(1):93-103. doi: 10.1016/j.cpet.2016.08.006. Epub 2016 Sep 19.
9
Intraarterial 131I-MIBG therapy of neuroendocrine tumors with liver metastases.肝转移神经内分泌肿瘤的动脉内131I-间碘苄胍治疗
Nuklearmedizin. 2010;49(1):N2-3.
10
Recent advances in nuclear medicine in endocrine oncology.核医学在内分泌肿瘤学中的最新进展。
Curr Opin Oncol. 2017 Jan;29(1):1-6. doi: 10.1097/CCO.0000000000000338.
引用本文的文献
1
Framework to calculate Ac, Lu, and Tb radiation dose and biological effect in metastatic castration-resistant prostate cancer treatment.计算转移性去势抵抗性前列腺癌治疗中Ac、Lu和Tb辐射剂量及生物学效应的框架。
Med Phys. 2025 Aug;52(8):e18035. doi: 10.1002/mp.18035.
2
Mechanisms of Action of AGuIX as a Pan-Cancer Nano-Radiosensitizer: A Comprehensive Review.AGuIX作为一种泛癌纳米放射增敏剂的作用机制：综述
Pharmaceuticals (Basel). 2025 Apr 2;18(4):519. doi: 10.3390/ph18040519.
3
Advancements in delivery systems for dietary polyphenols in enhancing radioprotection effects: challenges and opportunities.膳食多酚递送系统在增强辐射防护作用方面的进展：挑战与机遇
NPJ Sci Food. 2025 Apr 14;9(1):51. doi: 10.1038/s41538-025-00419-6.
4
177Lu-Labeled Antibody-Drug Conjugate: A Dual-Mechanistic Treatment Modality in Solid Tumors.177镥标记的抗体-药物偶联物：实体瘤的双机制治疗方式
Mol Cancer Ther. 2025 Jun 4;24(6):907-919. doi: 10.1158/1535-7163.MCT-24-0254.
5
Improvement of End-of-Synthesis Radiochemical Purity of Lu-DOTA-PSMA-Ligands with Alternative Synthesis Approaches: Conversion Upswing and Side-Products Minimization.采用替代合成方法提高镥-多胺多羧基配体-前列腺特异性膜抗原配体合成终产物的放射化学纯度：转化率上升及副产物最小化
Pharmaceutics. 2024 Nov 30;16(12):1535. doi: 10.3390/pharmaceutics16121535.
6
Exploring key features of selectivity in somatostatin receptors through molecular dynamics simulations.通过分子动力学模拟探索生长抑素受体选择性的关键特征。
Comput Struct Biotechnol J. 2024 Mar 18;23:1311-1319. doi: 10.1016/j.csbj.2024.03.005. eCollection 2024 Dec.
7
Calculation of alpha particle single-event spectra using a neural network.使用神经网络计算α粒子单事件能谱。
Front Oncol. 2024 Oct 2;14:1394671. doi: 10.3389/fonc.2024.1394671. eCollection 2024.
8
Nanoscale Radiotheranostics for Cancer Treatment: From Bench to Bedside.用于癌症治疗的纳米尺度放射性诊疗剂：从基础到临床。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 Sep-Oct;16(5):e2006. doi: 10.1002/wnan.2006.
9
The application of radionuclide therapy for breast cancer.放射性核素疗法在乳腺癌治疗中的应用。
Front Nucl Med. 2024 Jan 10;3:1323514. doi: 10.3389/fnume.2023.1323514. eCollection 2023.
10
Enhancement of gold-curcumin nanoparticle mediated radiation response for improved therapy in cervical cancer: a computational approach and predictive pathway analysis.金-姜黄素纳米颗粒介导的宫颈癌辐射反应增强以改善治疗效果：一种计算方法和预测途径分析
Discov Nano. 2024 Sep 18;19(1):153. doi: 10.1186/s11671-024-04104-7.
本文引用的文献
1
Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.Bi-PSMA-617靶向α放射性核素疗法治疗转移性去势抵抗性前列腺癌
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1099-1100. doi: 10.1007/s00259-017-3657-9. Epub 2017 Mar 2.
2
Radionuclide Therapy for Neuroendocrine Tumors.神经内分泌肿瘤的放射性核素治疗
Curr Oncol Rep. 2017 Feb;19(2):9. doi: 10.1007/s11912-017-0567-8.
3
Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients.预测放射性栓塞术后生存的治疗前因素：389例患者的单中心经验
Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1185-1193. doi: 10.1007/s00259-017-3646-z. Epub 2017 Feb 14.
4
Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors.钇-90微球放射性栓塞治疗不可切除的转移性神经内分泌肝脏肿瘤的单机构经验
J Gastroenterol Hepatol. 2017 Sep;32(9):1617-1623. doi: 10.1111/jgh.13752.
5
Differences in Radiation Activity Between Glass and Resin 90Y Microspheres in Treating Unresectable Hepatic Cancer.玻璃与树脂90Y微球治疗不可切除肝癌时的辐射活性差异
Health Phys. 2017 Mar;112(3):300-304. doi: 10.1097/HP.0000000000000631.
6
Sc-PSMA-617 for radiotheragnostics in tandem with Lu-PSMA-617-preclinical investigations in comparison with Ga-PSMA-11 and Ga-PSMA-617.用于放射诊断的Sc-PSMA-617与Lu-PSMA-617联合——与Ga-PSMA-11和Ga-PSMA-617相比的临床前研究
EJNMMI Res. 2017 Dec;7(1):9. doi: 10.1186/s13550-017-0257-4. Epub 2017 Jan 19.
7
Resin Versus Glass Microspheres for Y Transarterial Radioembolization: Comparing Survival in Unresectable Hepatocellular Carcinoma Using Pretreatment Partition Model Dosimetry.树脂微球与玻璃微球用于 Y 型经动脉放射性栓塞治疗：使用预处理分区模型剂量学比较不可切除肝细胞癌的生存情况。
J Nucl Med. 2017 Aug;58(8):1334-1340. doi: 10.2967/jnumed.116.184713. Epub 2017 Jan 12.
8
Assessing Intra-arterial Complications of Planning and Treatment Angiograms for Y-90 Radioembolization.评估Y-90放射性栓塞治疗血管造影规划与治疗过程中的动脉内并发症
Cardiovasc Intervent Radiol. 2017 May;40(5):704-711. doi: 10.1007/s00270-016-1555-3. Epub 2017 Jan 11.
9
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.镥[177Lu]奥曲肽治疗中肠神经内分泌肿瘤的3期试验
N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.
10
Personnel dose reduction in Y microspheres liver-directed radioembolization: from interventional radiology suite to patient ward.钇微球肝脏导向放射性栓塞术中人员剂量减少：从介入放射科手术室到患者病房
Br J Radiol. 2017 Mar;90(1071):20160591. doi: 10.1259/bjr.20160591. Epub 2016 Dec 20.
Zotero 插件